Share Prices & Company Research

Market News

28 Jul 2021 | 12:09

GlaxoSmithKline Q2 profits, revenue jump

(Sharecast News) - GlaxoSmithKline said on Wednesday that it expects full-year earnings to be towards the top end of its guidance range as it reported a jump in second-quarter profit and revenues. Adjusted operating profit for the quarter rose 23% to £2.2bn, while total turnover was up 6% at £8.09bn. Adjusted earnings per share came in at 28.1p, beating analysts' expectations of 19.9p.

Turnover in the pharmaceuticals segment was 3% higher at £4.2bn, driven by strong growth in new and specialty products, and a prior year comparator that was impacted by the destocking of Covid-19 related first-quarter additional demand.

Vaccines turnover rose 39% to £1.6bn, driven mainly by pandemic adjuvant sales, higher demand for DTPa-containing vaccines in the US and increased demand for Bexsero in the US and Europe. Vaccines turnover excluding pandemic vaccines grew 16% to £1.3bn.

In consumer healthcare, which is being spun off into a separate company, turnover fell 4% to £2.3bn.

Glaxo reaffirmed its guidance for 2021 for a decline of mid to high-single digit percent adjusted earnings per share (EPS) and constant exchange rates (CER), excluding any contribution from Covid solutions.

In addition, following its "strong" Q2 performance, the company said it is likely to deliver full-year adjusted EPS towards "the better end" of its guidance range, which is for a decline of mid-to-high single-digit percentage at CER, excluding any contribution from Covid-19 solutions.

Chief executive Emma Walmsley said the group had delivered an "excellent" performance in Q2.

"We expect this positive momentum to continue through the second half of the year driving us towards the better end of our earnings guidance range for 2021, and meaningful performance improvement in 2022," she said. "We continue to strengthen our pipeline and are advancing well towards separation. Our clear priority is to focus on execution, unlocking the value of Consumer Healthcare and delivering the step-change in growth and performance we now see for GSK."

The shares shot up after the announcement and by 1225 BST were trading up 1.5% at 1,420.20p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.